LumiraDx to sell its point of care technology platform to Roche
| LMDXDelisted Stock | USD 0.42 0.02 4.55% |
Slightly above 61% of LumiraDx's investor base is looking to short. The analysis of current outlook of investing in LumiraDx suggests that many traders are alarmed regarding LumiraDx's prospects. LumiraDx's investing sentiment can be driven by a variety of factors including economic data, LumiraDx's earnings reports, geopolitical events, and overall market trends.
LumiraDx |
LumiraDx agrees to sell its point of care technology to Roche for 295 million, with additional payment for funding until acquisition closure.
Read at seekingalpha.com
 |
LumiraDx Fundamental Analysis
We analyze LumiraDx's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of LumiraDx using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of LumiraDx based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Revenue
Revenue Comparative Analysis
LumiraDx is currently under evaluation in revenue category among its peers. Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
LumiraDx Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with LumiraDx stock to make a market-neutral strategy. Peer analysis of LumiraDx could also be used in its relative valuation, which is a method of valuing LumiraDx by comparing valuation metrics with similar companies.
Peers
LumiraDx Related Equities
| SHC | Sotera Health | 1.65 | ||||
| XGN | Exagen | 1.41 | ||||
| BDSX | Biodesix | 0.68 | ||||
| FONR | Fonar | 0.26 | ||||
| BNR | Burning Rock | 1.22 | ||||
| ENZ | Enzo Biochem | 4.36 | ||||
| SERA | Sera Prognostics | 7.21 | ||||
| DRIO | DarioHealth Corp | 12.50 |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Other Consideration for investing in LumiraDx Stock
If you are still planning to invest in LumiraDx check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the LumiraDx's history and understand the potential risks before investing.
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |